Xenogen®
Xenogen®, a publically held company (Nasdaq:
XGEN), is a leading biotechnology company and developer of
in vivo biophotonic technology, which allows real-time, non-invasive
exploration of genes, proteins, pathogens, and tumor cells
in living animals. Xenogen's® imaging technology from
its VivoVision® Systems utilize in vivo biophotonic technology
for broad commercial application in genomics, drug discovery,
and toxicology testing. Xenogen® licenses its patented
technology and provides products and services to pharmaceutical
and biotechnology firms, as well as research institutions.
Xenogen® is the leader in developng biophotonic
research tools that play a significant role include oncology,
inflammation, and metabolic and infectious disease. The company's
patented, proprietary, and licensable Xenogen technologies,
currently in place, include innovative imaging technologies,
light producing cells, microorganisms, and animals, as well
as a comprehensive array of genetically modified animal model
programs. Xenogen believes that its systems, solutions, and
biosciences can make animal testing more humane and efficient
across a broad range of applications. New applications for
existing technologies and future technologies for use in genomic
research and safety/toxicology are also under development.
More information can be found by visiting www.xenogen.com.
|
